Please ensure Javascript is enabled for purposes of website accessibility

What Does Remdesivir's Promising Study Mean for Gilead's Stock?

By Zhiyuan Sun – Updated May 1, 2020 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The first standard-of-care drug for treating COVID-19 may be coming sooner than we think.

Results from an interim analysis of COVID-19 patients receiving Gilead Sciences' (GILD -1.43%) antiviral drug Remdesivir in phase 3 clinical trials conducted by the National Institute of Allergy and Infectious Diseases (NIAID) were announced April 29. They showed that the drug met its primary endpoint in improving patients' recovery, but failed to achieve statistical significance in improving patients' survival.

Does this mean Remdesivir is unable to save lives? Or is there something investors and skeptics have overlooked?

A lab worker uses a pipette.

Image source: Getty Images.

How do the numbers look?

During an interim analysis, COVID-19 patients who were administered Remdesivir took 11 days to recover, compared with 15 days for patients who were administered the placebo (31% improvement). This was the primary endpoint of the trial, and it was achieved with robust statistical significance.

However, the trial barely missed another endpoint, reduction in mortality rate (the number of patients deceased out of total patients enrolled in a clinical trial cohort). In all, 11.6% of patients in the placebo cohort died, compared with 8% of patients in the Remdesivir cohort. These results barely missed the threshold for statistical significance. 

So can Remdesivir save lives?

It's highly likely. Now, readers may be wondering how it is possible for a drug to save patients' lives if a study showed that it doesn't reduce mortality rate. To better understand this, let's brush up on some of the basics of clinical trial design and statistics. 

In large, late-stage trials such as this one, the principal investigator (Gilead) will use an independent Data and Safety Monitoring Board (DSMB) to monitor trial progress and make recommendations based on periodic reviews of unblinded data. 

If an experimental drug demonstrates efficacy with robust statistical significance and is targeting a condition in dire need of treatment, the DSMB will recommend early termination of the trial and rush the experimental drug to approval.

In the case of Remdesivir, this is exactly what happened. The primary endpoint of the trial was to measure time to recovery, and when it was met, the trial was terminated for outstanding efficacy. 

That means one reason the survival benefit didn't pass the statistical test was because the trial did not progress to completion. There have been case studies in which an experimental drug did not exhibit statistical improvement in mortality rates in the early stages, but the DSMB recommended the continuation of the study, and at completion the benefit turned out to be highly statistically significant.

Statistical power can be an issue. If an experimental drug is hypothesized to have a small or moderate benefit to patients' survival, then more patients need to be enrolled in order for the trial to demonstrate statistical significance.

For the sake of argument, if Remdesivir had an actual, absolute survival benefit of 5% (based on the difference between the treatment arm and the control arm), it would be almost impossible to demonstrate this in a study of 20 patients taking Remdesivir or placebo. However, if the study enrolled 2,000 patients -- or 20,000 -- then the benefit will be easily witnessed and deemed highly statistically significant. 

I do not think the 1,063 patients enrolled in the NIAID trial were sufficient to determine whether Remdesivir has a small or moderate benefit. However, we do know now that the drug works against the COVID-19 coronavirus, and more likely than not will prove to save lives in larger clinical trials.

Additionally, readers should not be dismayed by a small absolute survival benefit. Again, for the sake of argument, if the mortality rate was 5% for 10,000 COVID-19 patients who took Remdesivir and 10% for 10,000 COVID-19 patients who didn't, then the difference among the two cohorts would amount to 500 lives saved by the treatment.

What about the China study?

At this point, skeptics may object to efficacy claims by referring to another study conducted in China, which determined that Remdesivir showed no survival benefit against placebo.

That study was terminated early due to low enrollment, and it suffers even more strongly from the same statistical power problem. The trial involved just 237 patients, making it even more difficult to show the survival difference between Remdesivir and the placebo. As a result, the data from the larger trial overshadows the results published in this one. 

Does this make the stock a buy?

In short, yes. In another article, I discussed the possibility of a second or third wave of COVID-19 infection based on historical precedents for respiratory pandemics, and Remdesivir could help if it is approved in time. 

The U.S. Food and Drug Administration (FDA) has begun procedures for emergency advancement of Remdesivir. In addition, NIAID director Dr. Anthony Fauci has claimed the drug is now "the standard of care" for COVID-19. By year's end, Gilead said it will have "millions" of doses of the antiviral therapy stockpiled. 

With all that said, a promising catalyst to combat a global pandemic is not the only area of growth in Gilead's pipeline. Recently, the company has greatly expanded its exposure in the field of immuno-oncology with the acquisitions of Forty Seven and Kite Pharma. This is definitely a stock biotech investors do not want to miss.

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.86 (-1.43%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.